aceneuramic acid extended-release (Ace-ER)

Phase 3

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Hereditary Inclusion Body Myopathy

Clinical Trial

Last updated: 12/4/2025

Developer

RARE

Ultragenyx Pharmaceutical Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

OTC Deficiency

Osteogenesis Imperfecta

MPS 7

MPS IIIA

Angelman Syndrome